Cytosorbents Corporation (NASDAQ:CTSO) Shares Acquired by Skylands Capital LLC

Skylands Capital LLC grew its holdings in shares of Cytosorbents Corporation (NASDAQ:CTSO - Free Report) by 7.9% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,002,702 shares of the medical research company's stock after buying an additional 221,080 shares during the period. Skylands Capital LLC owned 4.80% of Cytosorbents worth $3,003,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of CTSO. Avenir Corp grew its holdings in shares of Cytosorbents by 4.0% during the fourth quarter. Avenir Corp now owns 3,093,946 shares of the medical research company's stock worth $2,815,000 after purchasing an additional 118,387 shares during the last quarter. Raymond James Financial Inc. purchased a new position in Cytosorbents during the 4th quarter worth approximately $99,000. Northern Trust Corp increased its position in Cytosorbents by 22.3% during the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company's stock worth $83,000 after buying an additional 16,701 shares during the period. Renaissance Technologies LLC lifted its stake in Cytosorbents by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company's stock valued at $80,000 after buying an additional 8,400 shares during the last quarter. Finally, Key Client Fiduciary Advisors LLC boosted its holdings in shares of Cytosorbents by 127.0% in the first quarter. Key Client Fiduciary Advisors LLC now owns 78,457 shares of the medical research company's stock valued at $78,000 after acquiring an additional 43,900 shares during the period. 32.87% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Wall Street Zen started coverage on Cytosorbents in a research report on Wednesday, May 21st. They issued a "hold" rating on the stock. HC Wainwright restated a "neutral" rating and set a $1.00 price target on shares of Cytosorbents in a research note on Thursday, May 15th. Finally, D. Boral Capital reaffirmed a "buy" rating and set a $10.00 price target on shares of Cytosorbents in a report on Wednesday, June 25th.

Cytosorbents Stock Performance

NASDAQ:CTSO traded up $0.05 during mid-day trading on Monday, reaching $1.28. The stock had a trading volume of 104,594 shares, compared to its average volume of 148,673. Cytosorbents Corporation has a twelve month low of $0.70 and a twelve month high of $1.61. The business has a 50 day simple moving average of $1.00 and a 200 day simple moving average of $1.01. The firm has a market capitalization of $80.14 million, a price-to-earnings ratio of -4.57 and a beta of 1.05. The company has a debt-to-equity ratio of 0.98, a quick ratio of 2.30 and a current ratio of 2.61.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last issued its earnings results on Wednesday, May 14th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.02. Cytosorbents had a negative return on equity of 105.04% and a negative net margin of 41.77%. The business had revenue of $8.73 million during the quarter, compared to the consensus estimate of $9.01 million. On average, analysts expect that Cytosorbents Corporation will post -0.3 earnings per share for the current fiscal year.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.